OREANDA-NEWS. January 22, 2016. ResMed Inc. (NYSE: RMD) today announced results for its quarter ended December 31, 2015. Revenue for the quarter was \\$454.5 million, a 7 percent increase compared with the quarter ended December 31, 2014; this is a 13 percent increase on a constant currency basis.  

"We remain focused on delivering strong long-term growth from our sleep-disordered breathing and respiratory care businesses.  Our team continued to deliver double-digit constant currency growth this quarter," said

Mick Farrell, ResMed's chief executive officer. "Our Americas region was a significant contributor this quarter, as our customers continued to show their strong preference for our offerings, including Air Solutions cloud-based software, AirSense devices, and AirFit patient interface systems.

"We have expanded our respiratory care business into the field of long-term oxygen therapy. Last week we announced a definitive agreement to acquire Inova Labs in Austin, Texas. This will add portable oxygen concentrators, complementing our non-invasive ventilators, and providing yet another ResMed therapy option for patients with chronic obstructive pulmonary disease, or COPD." 

Farrell continued, "In the 15 months since we launched our Air Solutions platform, ResMed has transformed into a tech-driven medical device company. As the global leader of connected care for medical devices, we are liberating healthcare data, improving outcomes, and unlocking value by providing actionable information for patients, physicians, providers and payors, literally every morning."

Analysis of second quarter results
In the second quarter of fiscal year 2016, revenue in the Americas was \\$269.5 million, a 17 percent increase over the prior year's quarter. Revenue in combined EMEA and APAC was \\$185.0 million, a 4 percent decrease compared with the quarter ended December 31, 2014; this is a 7 percent increase on a constant currency basis.

Gross margin in the second quarter was 58.6 percent, but this included a one-time benefit relating to the release of \\$2.4 million in accrued expenses associated with the SERVE-HF field safety notice.  Excluding this benefit, gross margin for Q2 FY16 was 58.1 percent; this is lower than the prior year's quarter, mainly due to declines in average selling prices and an unfavorable geographic and product mix.

Income from operations for the quarter was \\$108.0 million, a 1 percent decrease compared with the quarter ended December 31, 2014. Non-GAAP income from operations for the quarter was \\$116.9 million, a 5 percent increase compared with the quarter ended December 31, 2014. 

Selling, general and administrative expenses were \\$118.2 million for the second quarter of fiscal year 2016, a 4 percent decrease over the quarter ended December 31, 2014; this is a 4 percent increase on a constant currency basis. SG&A expenses improved to 26.0 percent of revenue in the quarter, compared with 29.0 percent in the quarter ended December 31, 2014.  

Research and development expenses were \\$29.0 million for the second quarter of fiscal year 2016, or 6.4 percent of revenue. R&D expenses decreased by 1 percent compared with the quarter ended December 31, 2014; this is a 14 percent increase on a constant currency basis.

Amortization of acquired intangible assets was \\$4.4 million during the quarter. Stock-based compensation costs incurred during the quarter of \\$11.5 million consisted of expenses associated with employee equity grants, and the company's employee stock purchase plan. 

Net income for the quarter was \\$90.5 million, a 1 percent decrease compared with the quarter ended December 31, 2014. Non-GAAP net income for the quarter ended December 31, 2015 was \\$97.5 million, a 5 percent increase compared with the quarter ended December 31, 2014 (non-GAAP measures exclude the SERVE-HF accrual release, amortization of acquired intangibles, and \\$5.2 million in net restructuring expenses associated with rationalizing our European facilities). 

GAAP diluted earnings per share for the quarter were \\$0.64.

Non-GAAP diluted earnings per share for the quarter were \\$0.69. 

Cash flow from operations for the quarter was \\$147.4 million.

Share repurchase program
During the quarter, the company repurchased 700,000 shares at a cost of \\$40.1 million, as part of its ongoing capital management program. 

Dividend program
The ResMed board of directors today declared a quarterly dividend of \\$0.30 per share. The dividend will have a record date of February 11, 2016, payable on March 17, 2016. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be February 9, 2016 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 10, 2016 through February 11, 2016 inclusive. 

Webcast details
ResMed will discuss its financial and business results and outlook on its webcast at 1:30 p.m. U.S. Pacific Standard Time today. The live webcast of the call can be accessed on ResMed's Investor Relations website at investors.resmed.com.  Please go to this section of the website and click on the icon for the "Q2 2016 earnings webcast" to register and listen to the live webcast. The online archive of the broadcast will be available on ResMed's website after the live call. In addition, a telephone replay of the conference call will be available approximately two hours after the call by dialing 855-859-2056 (U.S.) and +1 404-537-3406 (international) and entering a passcode of 4360562. The telephone replay will be available until February 4, 2016.

About ResMed
The global team at ResMed (NYSE:RMD) is united in the commitment to change millions of lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter.

Safe harbor statement
Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements—including statements regarding ResMed's projections of future revenue or earnings,  expenses, new product development, new product launches and new markets for its products and the integration of acquisitions—are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission.  ResMed does not undertake to update its forward-looking statements.

Investors:

Agnes Lee
Senior Director, Investor Relations
(858) 836-5971
investorrelations@resmed.com

News Media:

Alison Graves
Director, Global Corporate Communications
(858) 836-6789
news@resmed.com

ResMed Inc and Subsidiaries

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

Three Months Ended

December 31,

Six Months Ended

December 31,

2015

2014

2015

2014



Net revenue

\\$454,540

\\$422,952

\\$866,187

\\$803,351

Cost of sales

190,433

159,730

363,461

302,816

SERVE-HF accrual release(1)

(2,402)

-

(2,402)

-

Gross profit

266,509

263,222

505,128

500,535



Operating expenses:



Selling, general and administrative

118,219

122,520

229,314

233,041

Research and development

28,970

29,294

56,162

59,318

Restructuring expenses(1)

6,914

-

6,914

-

Amortization of acquired intangible assets(1)

4,429

2,262

6,736

4,355

Total operating expenses

158,532

154,076

299,126

296,714

Income from operations(1)

107,977

109,146

206,002

203,821



Other income (expenses), net:



Interest income (expense), net

2,476

5,418

5,898

11,003

Other, net

3,242

947

1,239

2,617

Total other income (expenses), net

5,718

6,365

7,137

13,620



Income before income taxes

113,695

115,511

213,139

217,441

Income taxes

23,178

24,330

42,220

43,001

Net income(1)

\\$90,517

\\$91,181

\\$170,919

\\$174,440



Basic earnings per share

\\$0.65

\\$0.65

\\$1.22

\\$1.25

Diluted earnings per share

\\$0.64

\\$0.64

\\$1.21

\\$1.22

Non-GAAP diluted earnings per share(1)

\\$0.69

\\$0.65

\\$1.27

\\$1.25



Basic shares outstanding

139,926

140,048

140,118

140,104

Diluted shares outstanding

141,148

142,202

141,532

142,468


(1)

 See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

ResMed Inc And Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited - In thousands)

December 31

June 30,

2015

2015

Assets

Current assets:

Cash and cash equivalents

\\$658,804

\\$717,249

Accounts receivable, net

331,747

362,568

Inventories

237,463

246,859

Prepayments, deferred income taxes and other current assets

122,827

117,506

Total current assets

1,350,841

1,444,182

Property, plant and equipment, net

375,224

387,758

Goodwill and other intangible assets, net

466,418

311,403

Deferred income taxes and other non-current assets

46,528

40,917

Total non-current assets

888,170

740,078

Total assets

\\$2,239,011

\\$2,184,260

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

\\$67,580

\\$81,112

Accrued expenses

147,662

132,976

Deferred revenue

36,101

36,097

Income taxes payable

12,427

16,278

Deferred income taxes

815

796

Short-term debt

985

-

Total current liabilities

265,570

267,259

Non-current liabilities:

Deferred income taxes

15,665

8,062

Deferred revenue

28,928

19,284

Income taxes payable

1,754

1,754

Other long term liabilities

2,232

-

Long-term debt

400,591

300,594

Total non-current liabilities

449,170

329,694

Total liabilities

714,740

596,953

Stockholders' Equity:

Common stock

560

562

Additional paid-in capital

1,268,374

1,228,795

Retained earnings

2,062,885

1,976,020

Treasury stock

(1,546,611)

(1,444,554)

Accumulated other comprehensive income

(260,937)

(173,516)

Total stockholders' equity

\\$1,524,271

\\$1,587,307

Total liabilities and stockholders' equity

\\$2,239,011

\\$2,184,260

ResMed Inc And Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)

Six Months Ended

December 31,

2015

2014

Cash flows from operating activities:

Net income

\\$170,919

\\$174,440

Adjustment to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

39,920

37,451

Impairment of long-lived asset

2,815

-

Changes in fair value of business combination contingent consideration

(105)

(132)

Gain on disposal of business

-

(709)

Stock-based compensation costs

23,841

23,084

Excess tax benefit from stock-based compensation arrangements

(10,710)

(10,889)

Impairment of cost method investment

750

-

Changes in operating assets and liabilities, net of effect of acquisitions:

Accounts receivable, net

24,533

11,067

Inventories, net

8,751

(64,406)

Prepaid expenses, net deferred income taxes and other current assets

14,398

(4,309)

Accounts payable, accrued expenses and other liabilities

(5,600)

26,941

Net cash provided by operating activities

269,512

192,538

Cash flows from investing activities:

Purchases of property, plant and equipment

(30,934)

(39,675)

Patent registration costs

(4,902)

(4,810)

Business acquisitions, net of cash acquired

(152,118)

(17,781)

Investments in cost-method investments

(7,582)

(10,500)

Proceeds from sale of business

-

468

Payments on maturity of foreign currency contracts

(28,326)

(28,300)

Net cash used in investing activities

(223,862)

(100,598)

Cash flows from financing activities:

Proceeds from issuance of common stock, net

8,066

9,931

Excess tax benefit from stock-based compensation arrangements

10,710

10,889

Purchases of treasury stock

(102,058)

(84,055)

Payment of business combination contingent consideration

(1,120)

(458)

Proceeds from borrowings, net of borrowing costs

200,000

149,000

Repayment of borrowings

(100,160)

(19)

Dividends paid

(84,054)

(78,477)

Net cash (used in) / provided by financing activities

(68,616)

6,811

Effect of exchange rate changes on cash

(35,479)

(123,786)

Net increase / (decrease) in cash and cash equivalents

(58,445)

(25,035)

Cash and cash equivalents at beginning of period

717,249

905,730

Cash and cash equivalents at end of period

658,804

880,695

Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US\\$ thousands, except share and per share data)


The measure, "non-GAAP income from operations" is reconciled with GAAP income from operations below:

Three Months Ended

December 31,

Six Months Ended

December 31,

2015

2014

2015

2014

GAAP income from operations

\\$107,977

\\$109,146

\\$206,002

\\$203,821

SERVE-HF accrual release (A)

(2,402)

-

(2,402)

-

Restructuring expenses (A)

6,914

-

6,914

-

Amortization of acquired intangible assets (A)

4,429

2,262

6,736

4,355

Non-GAAP income from operations (excluding the impact of SERVE-HF accrual release, restructuring expenses and amortization of acquired intangible assets)

\\$116,918

\\$111,408

\\$217,250

\\$208,176


The measures "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

Three Months Ended

December 31,

Six Months Ended

December 31,

2015

2014

2015

2014

GAAP net income

\\$90,517

\\$91,181

\\$170,919

\\$174,440

SERVE-HF accrual release, net of tax (A)

(1,682)

-

(1,682)

-

Restructuring expenses, net of tax (A)

5,204

-

5,204

-

Amortization of acquired intangible assets, net of tax (A)

3,439

1,707

5,156

3,308

Non-GAAP net income (A)

\\$97,478

\\$92,888

\\$179,597

\\$177,748

Diluted shares outstanding

141,148

142,202

141,532

142,468

GAAP diluted earnings per share

\\$0.64

\\$0.64

\\$1.21

\\$1.22

Non-GAAP diluted earnings per share (A)

\\$0.69

\\$0.65

\\$1.27

\\$1.25


(A)  

ResMed excludes the impact of release of SERVE-HF accrual, restructuring expenses and amortization of acquired intangible assets from their evaluation of ongoing operations and believes investors benefit from excluding these charges to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that diluted earnings per share, which exclude the impact of the SERVE-HF accrual release, restructuring expenses and amortization of acquired intangible assets, is an additional measure of performance investors can use to compare operating results between reporting periods.




ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed's performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.